Omega Therapeutics (OMGA) Stock Forecast, Price Target & Predictions
OMGA Stock Forecast
Omega Therapeutics stock forecast is as follows: an average price target of $9.00 (represents a 975.40% upside from OMGA’s last price of $0.84) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
OMGA Price Target
The average price target for Omega Therapeutics (OMGA) is $9.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $7.00. This represents a potential 975.40% upside from OMGA's last price of $0.84.
OMGA Analyst Ratings
According to 2 Wall Street analysts, Omega Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for OMGA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Omega Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 03, 2024 | Edward Tenthoff | Piper Sandler | $9.00 | $3.01 | 199.00% | 975.40% |
| Apr 01, 2024 | Keay Nakae | Loop Capital Markets | $7.00 | $3.65 | 91.78% | 736.42% |
| Dec 08, 2022 | H.C. Wainwright | $11.00 | $6.30 | 74.60% | 1214.37% |
The latest Omega Therapeutics stock forecast, released on Apr 03, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $9.00, which represents a 199.00% increase from the stock price at the time of the forecast ($3.01), and a 975.40% increase from OMGA last price ($0.84).
Omega Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $8.00 |
| Last Closing Price | $0.84 | $0.84 | $0.84 |
| Upside/Downside | -100.00% | -100.00% | 855.91% |
In the current month, the average price target of Omega Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Omega Therapeutics's last price of $0.84. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 15, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 15, 2024 | Wedbush | Buy | Buy | Hold |
| Aug 15, 2024 | Raymond James | Underperform | Underperform | Hold |
| Jun 18, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Jun 18, 2024 | Raymond James | Buy | Buy | Hold |
| Jun 18, 2024 | Raymond James | Outperform | Initialise | |
| May 07, 2024 | Chardan Capital | Underperform | Underperform | Hold |
| May 07, 2024 | Piper Sandler | Buy | Buy | Hold |
| Apr 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 01, 2024 | Chardan Capital | Buy | Buy | Hold |
Omega Therapeutics's last stock rating was published by Piper Sandler on Nov 15, 2024. The company gave OMGA a "Overweight" rating, the same as its previous rate.
Omega Therapeutics Financial Forecast
Omega Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $831.00K | $759.00K | $516.00K | $735.00K | $595.00K | $476.00K | $268.00K |
| Avg Forecast | $1.08M | $1.08M | $1.08M | $1.08M | $1.48M | $700.00K | $956.14K | $1.16M | $450.00K | $442.86K | $378.57K | $314.29K | $257.50K | $101.20K | $51.50K | $338.53K |
| High Forecast | $1.96M | $1.96M | $1.96M | $1.78M | $2.84M | $1.27M | $956.21K | $1.16M | $483.87K | $805.75K | $688.79K | $571.83K | $468.51K | $101.20K | $51.50K | $406.23K |
| Low Forecast | $489.40K | $489.40K | $489.40K | $538.50K | $603.52K | $318.08K | $956.07K | $1.16M | $411.29K | $201.24K | $172.03K | $142.81K | $117.01K | $101.20K | $51.50K | $270.82K |
| # Analysts | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.88% | 2.00% | 1.64% | 2.85% | 5.88% | 9.24% | 0.79% |
Omega Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $450.00K, with a low forecast of $411.29K, and a high forecast of $483.87K. OMGA's average Quarter revenue forecast represents a -45.85% decrease compared to the company's last Quarter revenue of $831.00K (Sep 23).
Omega Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-22.90M | $-30.84M | $-25.82M | $-30.97M | $-25.59M | $-25.45M | $-19.63M |
| Avg Forecast | $-215.40K | $-215.40K | $-215.40K | $-215.40K | $-296.93K | $-140.00K | $-191.23K | $-232.86K | $-90.00K | $-88.57K | $-75.71K | $-62.86K | $-51.50K | $-20.24K | $-10.30K | $-24.80M |
| High Forecast | $-97.88K | $-97.88K | $-97.88K | $-107.70K | $-120.70K | $-63.62K | $-191.21K | $-232.83K | $-82.26K | $-40.25K | $-34.40K | $-28.56K | $-23.40K | $-20.24K | $-10.30K | $-19.84M |
| Low Forecast | $-391.91K | $-391.91K | $-391.91K | $-355.41K | $-567.31K | $-254.72K | $-191.24K | $-232.88K | $-96.77K | $-161.15K | $-137.76K | $-114.36K | $-93.70K | $-20.24K | $-10.30K | $-29.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | 258.58% | 407.32% | 410.74% | 601.31% | 1264.44% | 2470.82% | 0.79% |
undefined analysts predict OMGA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Omega Therapeutics's previous annual EBITDA (undefined) of $NaN.
Omega Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
| Net Income | - | - | - | - | - | - | - | - | - | $-22.25M | $-29.69M | $-24.06M | $-30.68M | $-25.61M | $-25.97M | $-20.37M |
| Avg Forecast | $-12.13M | $-9.01M | $-8.64M | $-8.82M | $-12.50M | $-14.62M | $-20.15M | $-18.36M | $-24.73M | $-29.15M | $-27.42M | $-32.38M | $-34.31M | $-32.68M | $-31.16M | $-25.47M |
| High Forecast | $-3.53M | $-2.62M | $-2.51M | $-3.97M | $-9.66M | $-4.25M | $-5.86M | $-5.34M | $-24.19M | $-8.48M | $-7.97M | $-9.42M | $-9.97M | $-32.68M | $-31.16M | $-20.38M |
| Low Forecast | $-25.06M | $-18.61M | $-17.85M | $-12.35M | $-15.91M | $-30.19M | $-41.61M | $-37.92M | $-25.80M | $-60.21M | $-56.63M | $-66.88M | $-70.85M | $-32.68M | $-31.16M | $-30.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.76% | 1.08% | 0.74% | 0.89% | 0.78% | 0.83% | 0.80% |
Omega Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. OMGA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Omega Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
| SG&A | - | - | - | - | - | - | - | - | - | $7.87M | $6.21M | $5.95M | $5.36M | $5.20M | $6.20M | $5.41M |
| Avg Forecast | $29.36M | $29.36M | $29.36M | $29.36M | $40.47M | $19.08M | $26.06M | $31.74M | $12.27M | $12.07M | $10.32M | $8.57M | $7.02M | $2.71M | $1.38M | $9.08M |
| High Forecast | $53.41M | $53.41M | $53.41M | $48.44M | $77.32M | $34.72M | $26.06M | $31.74M | $13.19M | $21.96M | $18.77M | $15.59M | $12.77M | $2.71M | $1.38M | $10.90M |
| Low Forecast | $13.34M | $13.34M | $13.34M | $14.68M | $16.45M | $8.67M | $26.06M | $31.73M | $11.21M | $5.49M | $4.69M | $3.89M | $3.19M | $2.71M | $1.38M | $7.26M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.65% | 0.60% | 0.70% | 0.76% | 1.92% | 4.49% | 0.60% |
Omega Therapeutics's average Quarter SG&A projection for Dec 23 is $12.27M, based on 3 Wall Street analysts, with a range of $11.21M to $13.19M. The forecast indicates a 55.88% rise compared to OMGA last annual SG&A of $7.87M (Sep 23).
Omega Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.40 | $-0.54 | $-0.48 | $-0.64 | $-0.54 | $-0.54 | $-0.43 |
| Avg Forecast | $-0.22 | $-0.16 | $-0.16 | $-0.16 | $-0.23 | $-0.27 | $-0.37 | $-0.33 | $-0.45 | $-0.53 | $-0.50 | $-0.59 | $-0.62 | $-0.59 | $-0.56 | $-0.57 |
| High Forecast | $-0.06 | $-0.05 | $-0.05 | $-0.07 | $-0.18 | $-0.08 | $-0.11 | $-0.10 | $-0.44 | $-0.15 | $-0.14 | $-0.17 | $-0.18 | $-0.59 | $-0.56 | $-0.57 |
| Low Forecast | $-0.45 | $-0.34 | $-0.32 | $-0.22 | $-0.29 | $-0.55 | $-0.75 | $-0.69 | $-0.47 | $-1.09 | $-1.03 | $-1.21 | $-1.28 | $-0.59 | $-0.56 | $-0.57 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.76% | 1.09% | 0.82% | 1.03% | 0.91% | 0.96% | 0.76% |
According to undefined Wall Street analysts, Omega Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OMGA previous annual EPS of $NaN (undefined).
Omega Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OMGA | Omega Therapeutics | $0.86 | $9.00 | 946.51% | Buy |
| PEPG | PepGen | $4.30 | $29.50 | 586.05% | Buy |
| AVTE | Aerovate Therapeutics | $2.56 | $13.00 | 407.81% | Hold |
| OLMA | Olema Pharmaceuticals | $6.14 | $27.00 | 339.74% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
| CMPX | Compass Therapeutics | $1.53 | $5.00 | 226.80% | Buy |
| GPCR | Structure Therapeutics | $31.48 | $99.00 | 214.49% | Buy |
| CVKD | Cadrenal Therapeutics | $11.45 | $32.00 | 179.48% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| PHVS | Pharvaris | $18.49 | $42.00 | 127.15% | Buy |
| MLTX | MoonLake Immunotherapeutics | $56.30 | $100.00 | 77.62% | Buy |
| ELVN | Enliven Therapeutics | $24.39 | $39.50 | 61.95% | Buy |
| CNTA | Centessa Pharmaceuticals | $17.60 | $23.25 | 32.10% | Buy |